Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.52 |
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19507907 | 0.86 | CA2 (0.49) | CA2CA1CA9CA12CA4 | |
| SCHEMBL5520877 | 0.85 | VCAM1 (0.47) | KIF11PTGS1PTGS2 | |
| SCHEMBL29793217 | 0.83 | KIF11 (0.60) | CA2CA1CA9CA12CA4 | |
| SCHEMBL1497086 | 0.83 | KIF11 (0.60) | CA2CA1CA9CA12CA4 | |
| SCHEMBL19750864 | 0.83 | KIF11 (0.47) | KIF11PTGS1PTGS2 | |
| SCHEMBL23633373 | 0.78 | CA2 (0.41) | CA2CA1CA9CA12CA4 | |
| SCHEMBL24333583 | 0.77 | CA2 (0.44) | CA2CA1CA9CA12CA4 | |
| SCHEMBL22606257 | 0.77 | APEX1 (0.47) | CA2CA1CA9CA12CA4 | |
| SCHEMBL22867071 | 0.76 | CA2 (0.55) | CA2CA1CA9CA12CA4 | |
| SCHEMBL28109693 | 0.76 | CA1 (0.46) | CA2CA1CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787799-B2 | Potent antiviral pyrazolopyridine compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787799-B2 | Potent antiviral pyrazolopyridine compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220119384-A1 | POTENT ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-04-21 | — | — | US | disclosed |
| US-11059817-B2 | Potent antiviral pyrazolopyridine compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787799-B2 | Potent antiviral pyrazolopyridine compounds | MAVS, VRK1, VRK2 | CA2 1980/4885CA1 4053/4885CA9 2806/4885 |
| US-20220119384-A1 | POTENT ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS | MAVS, VRK1, VRK2 | CA2 1980/4885CA1 4053/4885CA9 2806/4885 |
| US-11059817-B2 | Potent antiviral pyrazolopyridine compounds | MAVS, VRK1, VRK2 | CA2 1980/4885CA1 4053/4885CA9 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.